Viridian Therapeutics (VRDN) Competitors $19.23 +1.21 (+6.71%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$19.09 -0.14 (-0.73%) As of 08/22/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRDN vs. RDNT, OPCH, SHC, BTSG, WGS, CON, SGRY, PRVA, HTFL, and VCYTShould you be buying Viridian Therapeutics stock or one of its competitors? The main competitors of Viridian Therapeutics include RadNet (RDNT), Option Care Health (OPCH), Sotera Health (SHC), BrightSpring Health Services (BTSG), GeneDx (WGS), Concentra Group Holdings Parent (CON), Surgery Partners (SGRY), Privia Health Group (PRVA), Heartflow (HTFL), and Veracyte (VCYT). These companies are all part of the "healthcare" industry. Viridian Therapeutics vs. Its Competitors RadNet Option Care Health Sotera Health BrightSpring Health Services GeneDx Concentra Group Holdings Parent Surgery Partners Privia Health Group Heartflow Veracyte Viridian Therapeutics (NASDAQ:VRDN) and RadNet (NASDAQ:RDNT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends. Do analysts rate VRDN or RDNT? Viridian Therapeutics currently has a consensus price target of $37.00, indicating a potential upside of 92.41%. RadNet has a consensus price target of $71.60, indicating a potential upside of 2.14%. Given Viridian Therapeutics' higher possible upside, equities research analysts plainly believe Viridian Therapeutics is more favorable than RadNet.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viridian Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89RadNet 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.25 Which has more risk & volatility, VRDN or RDNT? Viridian Therapeutics has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Comparatively, RadNet has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500. Is VRDN or RDNT more profitable? RadNet has a net margin of -0.78% compared to Viridian Therapeutics' net margin of -112,806.88%. RadNet's return on equity of 2.41% beat Viridian Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Viridian Therapeutics-112,806.88% -78.95% -49.91% RadNet -0.78%2.41%0.82% Does the media refer more to VRDN or RDNT? In the previous week, RadNet had 19 more articles in the media than Viridian Therapeutics. MarketBeat recorded 21 mentions for RadNet and 2 mentions for Viridian Therapeutics. RadNet's average media sentiment score of 1.15 beat Viridian Therapeutics' score of 0.48 indicating that RadNet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral RadNet 13 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in VRDN or RDNT? 77.9% of RadNet shares are held by institutional investors. 1.6% of Viridian Therapeutics shares are held by company insiders. Comparatively, 5.6% of RadNet shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better valuation & earnings, VRDN or RDNT? RadNet has higher revenue and earnings than Viridian Therapeutics. RadNet is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViridian Therapeutics$300K5,234.41-$269.95M-$3.83-5.02RadNet$1.91B2.83$2.79M-$0.20-350.50 SummaryRadNet beats Viridian Therapeutics on 13 of the 17 factors compared between the two stocks. Get Viridian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRDN vs. The Competition Export to ExcelMetricViridian TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.57B$3.11B$5.81B$9.76BDividend YieldN/A2.23%4.39%4.06%P/E Ratio-5.0221.0031.3626.05Price / Sales5,234.41209.44387.8788.42Price / CashN/A44.5038.0259.36Price / Book4.818.129.536.60Net Income-$269.95M-$54.72M$3.26B$265.65M7 Day Performance3.72%2.62%2.14%2.00%1 Month Performance9.95%3.25%3.22%0.46%1 Year Performance27.77%10.82%30.18%18.88% Viridian Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRDNViridian Therapeutics1.5667 of 5 stars$19.23+6.7%$37.00+92.4%+27.8%$1.57B$300K-5.0250RDNTRadNet3.3027 of 5 stars$66.29-1.7%$71.60+8.0%+7.8%$5.19B$1.83B-331.4311,021News CoveragePositive NewsInsider TradeOPCHOption Care Health4.5388 of 5 stars$28.19-0.5%$35.75+26.8%-9.7%$4.60B$5.00B22.558,088News CoveragePositive NewsInsider TradeGap UpSHCSotera Health1.3701 of 5 stars$15.80+0.4%$16.00+1.3%+6.5%$4.47B$1.10B197.523,000News CoveragePositive NewsBTSGBrightSpring Health Services1.8003 of 5 stars$23.09+2.9%$25.67+11.2%+97.9%$3.98B$11.27B74.4935,000Positive NewsWGSGeneDx2.1843 of 5 stars$125.90-0.4%$101.63-19.3%+259.8%$3.63B$305.45M2,518.001,200News CoveragePositive NewsInsider TradeCONConcentra Group Holdings Parent2.3153 of 5 stars$22.85-1.7%$28.50+24.8%+1.0%$2.98B$1.90B19.2011,250News CoveragePositive NewsSGRYSurgery Partners3.0358 of 5 stars$22.49-1.4%$33.00+46.7%-29.8%$2.92B$3.11B-15.7315,000News CoveragePositive NewsPRVAPrivia Health Group4.2649 of 5 stars$21.37+0.5%$28.00+31.0%+5.4%$2.61B$1.74B194.291,140News CoverageAnalyst UpgradeHTFLHeartflowN/A$29.97-3.8%N/AN/A$2.53BN/A0.00699VCYTVeracyte2.8348 of 5 stars$30.07-0.5%$40.90+36.0%-3.1%$2.38B$445.76M91.12790News CoveragePositive News Related Companies and Tools Related Companies RDNT Competitors OPCH Competitors SHC Competitors BTSG Competitors WGS Competitors CON Competitors SGRY Competitors PRVA Competitors HTFL Competitors VCYT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRDN) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viridian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access